Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 9/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CDK2 | P24941 | 2/20 | 0.40 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.39 |
| ▸ | AKT2 | P31751 | 1/20 | 0.39 |
| ▸ | CDK7 | P50613 | 2/20 | 0.38 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27823115 | 0.85 | AKT1 (0.40) | AKT1AKT3AKT2LMNAMAPT | |
| SCHEMBL1791692 | 0.84 | MAPT (0.51) | MAPT | |
| SCHEMBL1792637 | 0.81 | ACHE (0.45) | AKT1LMNAMAPTRPS6KB1 | |
| SCHEMBL1791436 | 0.79 | MAPT (0.58) | LMNAMAPT | |
| SCHEMBL1790785 | 0.79 | RPS6KB1 (0.47) | AKT1LMNAMAPTRPS6KB1 | |
| SCHEMBL1791472 | 0.79 | MAPT (0.56) | AKT1LMNAMAPTNPSR1RPS6KB1 | |
| SCHEMBL1789169 | 0.77 | ACHE (0.48) | LMNAMAPTRPS6KB1 | |
| SCHEMBL1792171 | 0.77 | MAPT (0.45) | AKT1LMNAMAPTNPSR1RPS6KB1 | |
| SCHEMBL1791761 | 0.77 | DHFR (0.44) | LMNAMAPTRPS6KB1 | |
| SCHEMBL1792145 | 0.77 | KDM4E (0.43) | LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101959516-A | Combination therapy comprising quinoxaline PI3K alpha inhibitors for the treatment of cancer | EXELIXIS INC | 2011-01-26 | — | — | CN | disclosed |